Showing 6071-6080 of 9414 results for "".
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti
- Allergan's TEFLARO® OK'd for Pediatric Patientshttps://practicaldermatology.com/news/allergans-teflaro-oked-for-pediatric-patients/2458547/Allergan’s TEFLARO® (ceftaroline fosamil) is now indicated for pediatric patients, making it the first branded IV antibiotic approved for this population in more than a decade. The U.S. Food and Drug Administration (FDA) appr
- ASDSA Releases New Sun-Safety Model Legislationhttps://practicaldermatology.com/news/asdsa-releases-new-sun-safety-model-legislation/2458548/New model legislation from American Society for Dermatologic Surgery Association (ASDSA) provides state governments with a framework to permit the use of sunscreens in school and camp settings. The
- Robert Grant No Longer CEO of Alphaeonhttps://practicaldermatology.com/news/robert-grant-no-longer-ceo-of-alphaeon/2458550/Robert Grant is no longer CEO of Alphaeon, our sister site, Eyewiretoday.com has learned. After 3 years at
- GlobalMed Technologies Acquires Omnilux Medicalhttps://practicaldermatology.com/news/globalmed-technologies-acquires-omnilux-medical/2458551/GlobalMed Technologies (GMT) has acquired Omnilux Medical, the gold standard for medical and aesthetic Light Emitting Diode (LED) skincare. The asset acquisition includes three Omnilux Medical Systems, the Omnilux Revive2™, Omnilux Blue™ and Omnilux Plus™,
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee
- Novel Topical AD Drug Shows Promise in Phase 2 Studyhttps://practicaldermatology.com/news/novel-ad-drug-shows-promise-in-phase-2-study/2458555/Medimetriks’ MM36 (previously known as OPA-15406) performed well in a Phase 2 trial for the treatment of mild-to-moderate atopic dermatitis, a new study in in Journal of the American Academy of Dermatology shows. The investigational t
- AAD Survey: Many Use Sunscreen Incorrectlyhttps://practicaldermatology.com/news/aad-survey-many-use-sunscreen-incorrectly/2458561/Many people don’t understand SPF numbers on product labels, and some may not be using sunscreen properly, which could increase their skin cancer risk, the American Academy of Dermatology reports. In a 2016 survey, only 32 percent of respondents knew that an SPF 30 sunscreen do
- Dr. Brandt's Legacy Lives on with New Dr. Brandt® Skincare Advisory Boardhttps://practicaldermatology.com/news/dr-brandts-legacy-lives-on-with-new-dr-brandt-skincare-advisory-board/2458563/Dr. Brandt® Skincare is rolling out a new Advisory Board to elevate the brand and honor Dr. Brandt’s legacy of innovation in dermatology. Frederick Brandt died on April 5, 2015 in his home in Coconut Grove, Florida. The first